tradingkey.logo

Lantern Pharma Inc <LTRN.OQ> expected to post a loss of 48 cents a share - Earnings Preview

ReutersAug 8, 2025 12:58 PM
  • Lantern Pharma Inc LTRN.OQ LTRN.O is expected to show no change in quarterly revenue when it reports results on August 11 (estimated) for the period ending June 30 2025

  • ​LSEG's mean analyst estimate for Lantern Pharma Inc is for a loss of 48 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Lantern Pharma Inc is $25.00, about 80% above its last closing price of $4.99

This summary was machine generated August 8 at 12:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI